KR20010020779A - 약학 제품 - Google Patents

약학 제품 Download PDF

Info

Publication number
KR20010020779A
KR20010020779A KR1020000022108A KR20000022108A KR20010020779A KR 20010020779 A KR20010020779 A KR 20010020779A KR 1020000022108 A KR1020000022108 A KR 1020000022108A KR 20000022108 A KR20000022108 A KR 20000022108A KR 20010020779 A KR20010020779 A KR 20010020779A
Authority
KR
South Korea
Prior art keywords
pde5
sexual dysfunction
inhibition
pde5 inhibitor
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020000022108A
Other languages
English (en)
Korean (ko)
Inventor
에믹제프리토마스
퍼거슨케니쓰마이클
펄먼윌리엄어네스트
휘태커존스티븐
Original Assignee
추후보정
릴리 아이코스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20010020779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 추후보정, 릴리 아이코스 엘엘씨 filed Critical 추후보정
Publication of KR20010020779A publication Critical patent/KR20010020779A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020000022108A 1999-04-30 2000-04-26 약학 제품 Ceased KR20010020779A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30
US60/132,036 1999-04-30

Publications (1)

Publication Number Publication Date
KR20010020779A true KR20010020779A (ko) 2001-03-15

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020000022108A Ceased KR20010020779A (ko) 1999-04-30 2000-04-26 약학 제품
KR1020017013747A Ceased KR100577057B1 (ko) 1999-04-30 2000-04-26 단위 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020017013747A Ceased KR100577057B1 (ko) 1999-04-30 2000-04-26 단위 제형

Country Status (47)

Country Link
EP (2) EP1173181B3 (enExample)
JP (2) JP4975214B2 (enExample)
KR (2) KR20010020779A (enExample)
CN (2) CN1292264A (enExample)
AT (1) ATE251908T1 (enExample)
AU (3) AU3012900A (enExample)
BE (1) BE1012957A5 (enExample)
BR (2) BR0003046A (enExample)
CA (2) CA2371684C (enExample)
CH (2) CH1173181H1 (enExample)
CO (1) CO5170493A1 (enExample)
CZ (1) CZ296534B6 (enExample)
DE (3) DE10021266A1 (enExample)
DK (2) DK200000677A (enExample)
DZ (1) DZ3171A1 (enExample)
EA (2) EA005416B1 (enExample)
ES (2) ES2187234A1 (enExample)
FI (1) FI20000976A7 (enExample)
FR (1) FR2795646B1 (enExample)
GB (1) GB2351663A (enExample)
GR (1) GR1003575B (enExample)
HK (1) HK1041204B (enExample)
HR (2) HRP20010778B1 (enExample)
HU (2) HUP0001632A3 (enExample)
ID (1) ID25704A (enExample)
IE (1) IE20000315A1 (enExample)
IL (3) IL135817A0 (enExample)
IT (1) ITMI20000922A1 (enExample)
LT (1) LT4758B (enExample)
LU (1) LU90569B1 (enExample)
LV (1) LV12560B (enExample)
MX (2) MXPA00003997A (enExample)
NL (1) NL1015027C2 (enExample)
NO (2) NO20002097L (enExample)
NZ (2) NZ514882A (enExample)
PE (1) PE20010071A1 (enExample)
PL (2) PL339897A1 (enExample)
PT (2) PT102457A (enExample)
SE (1) SE0001518L (enExample)
SG (1) SG98384A1 (enExample)
SI (2) SI20361A (enExample)
SK (1) SK285415B6 (enExample)
SV (1) SV2002000055A (enExample)
TR (1) TR200001132A2 (enExample)
UA (1) UA72248C2 (enExample)
WO (1) WO2000066099A2 (enExample)
ZA (2) ZA200002058B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039357D1 (de) * 1999-08-03 2008-08-14 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
JP2004533402A (ja) * 2000-06-08 2004-11-04 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅｖインヒビターとしての四環系ジケトピペラジン化合物
AU2001271948A1 (en) * 2000-08-02 2002-02-13 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
CA2445620C (en) * 2001-06-05 2008-07-08 Lilly Icos Llc Tetracyclic compounds as pde5-inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR101663238B1 (ko) 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
EP3749370B1 (de) * 2018-02-07 2025-05-07 Smawa GmbH Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028902A1 (en) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones for the treatment of impotence
WO1995019978A1 (en) * 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
WO1996016657A1 (en) * 1994-11-26 1996-06-06 Pfizer Limited Bicyclic heterocyclic compounds for the treatment of impotence
WO1997003675A1 (en) * 1995-07-14 1997-02-06 Icos Corporation Use of cgmp-phosphodiesterase inhibitors to treat impotence
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
CZ358598A3 (cs) 1996-05-10 1999-03-17 Icos Corporation Karbolinové deriváty
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
EP1161255A4 (en) * 1999-03-08 2002-07-17 Merck & Co Inc METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
JP2002543128A (ja) * 1999-04-30 2002-12-17 リリー アイコス リミテッド ライアビリティ カンパニー 雌性覚醒障害の処置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028902A1 (en) * 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones for the treatment of impotence
WO1995019978A1 (en) * 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
WO1996016657A1 (en) * 1994-11-26 1996-06-06 Pfizer Limited Bicyclic heterocyclic compounds for the treatment of impotence
WO1997003675A1 (en) * 1995-07-14 1997-02-06 Icos Corporation Use of cgmp-phosphodiesterase inhibitors to treat impotence
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
erectile dysfuction [http://www.lef.org/magazine/mag98/july98_abs.html *
S10: cyclic nucleotide phosphodiesterases and erectile function, http://www.apsir.org/html/kualalumpur97.htm *

Also Published As

Publication number Publication date
LU90569B1 (fr) 2002-02-27
NO322013B1 (no) 2006-08-07
NL1015027C2 (nl) 2001-02-14
HU0200912D0 (en) 2002-04-29
LT4758B (lt) 2001-02-26
AU2004201988A1 (en) 2004-06-10
CZ20013879A3 (cs) 2002-04-17
ATE251908T1 (de) 2003-11-15
ZA200108900B (en) 2003-03-26
DE60005940T2 (de) 2004-07-29
IL135817A0 (en) 2001-05-20
LV12560A (en) 2000-11-20
DZ3171A1 (enExample) 2000-11-09
GR20000100153A (el) 2000-12-29
CN1384746A (zh) 2002-12-11
TR200001132A3 (tr) 2001-01-22
NO20002097L (no) 2001-10-26
DE60005940T3 (de) 2015-08-27
CH692478A5 (de) 2002-07-15
DE20007861U1 (de) 2000-08-24
DK200000677A (da) 2000-10-31
HU230369B1 (hu) 2016-03-29
NO20015275D0 (no) 2001-10-29
HRP20000243A2 (en) 2001-12-31
ITMI20000922A1 (it) 2001-10-26
CA2307101A1 (en) 2000-10-30
FI20000976L (fi) 2000-10-30
ES2187234A1 (es) 2003-05-16
NL1015027A1 (nl) 2000-10-31
HUP0200912A3 (en) 2003-07-28
SK15632001A3 (sk) 2002-02-05
EP1415652A2 (en) 2004-05-06
HUP0001632A3 (en) 2001-12-28
PT102457A (pt) 2000-11-30
UA72248C2 (en) 2005-02-15
PT1173181E (pt) 2004-02-27
LT2000035A (lt) 2000-11-27
NO20015275L (no) 2001-12-06
EA200000355A2 (ru) 2000-10-30
FR2795646A1 (fr) 2001-01-05
GB0010199D0 (en) 2000-06-14
HRP20010778B1 (en) 2005-04-30
DK1173181T3 (da) 2004-02-16
WO2000066099A2 (en) 2000-11-09
EP1415652A3 (en) 2004-05-12
ZA200002058B (en) 2000-11-02
JP4975214B2 (ja) 2012-07-11
LV12560B (en) 2001-04-20
DE60005940D1 (de) 2003-11-20
HK1041204B (en) 2004-03-05
JP2000336043A (ja) 2000-12-05
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
AU769946C (en) 2005-01-13
AU3012900A (en) 2000-11-02
IL146098A0 (en) 2002-07-25
SE0001518L (sv) 2000-10-31
FR2795646B1 (fr) 2002-08-16
CN1292264A (zh) 2001-04-25
ES2208317T7 (es) 2015-09-15
ES2208317T3 (es) 2004-06-16
SV2002000055A (es) 2002-07-03
WO2000066099A3 (en) 2001-01-18
SI20361A (sl) 2001-04-30
PL197813B1 (pl) 2008-04-30
CZ296534B6 (cs) 2006-04-12
BR0010181A (pt) 2003-02-25
BE1012957A5 (fr) 2001-06-05
PL339897A1 (en) 2000-11-06
CA2307101C (en) 2003-01-28
DE10021266A1 (de) 2000-11-16
BR0003046A (pt) 2002-07-23
EA005416B1 (ru) 2005-02-24
MXPA00003997A (es) 2002-03-08
ITMI20000922A0 (it) 2000-04-26
KR20020008396A (ko) 2002-01-30
SI1173181T1 (en) 2004-04-30
PL352629A1 (en) 2003-08-25
SG98384A1 (en) 2003-09-19
NZ504163A (en) 2001-11-30
EP1173181B1 (en) 2003-10-15
NZ514882A (en) 2003-08-29
EA200101008A1 (ru) 2002-04-25
DK1173181T6 (en) 2015-04-27
HUP0200912A2 (en) 2002-08-28
AU769946B2 (en) 2004-02-12
JP2002543116A (ja) 2002-12-17
EA200000355A3 (ru) 2001-02-26
SK285415B6 (sk) 2007-01-04
MXPA01010837A (es) 2002-11-07
CO5170493A1 (es) 2002-06-27
KR100577057B1 (ko) 2006-05-10
EP1173181A2 (en) 2002-01-23
FI20000976A7 (fi) 2000-10-30
NO20002097D0 (no) 2000-04-25
HUP0001632A2 (hu) 2001-05-28
SE0001518D0 (sv) 2000-04-26
TR200001132A2 (tr) 2001-01-22
CA2371684C (en) 2007-10-23
EP1173181B3 (en) 2015-03-25
CA2371684A1 (en) 2000-11-09
AU4490800A (en) 2000-11-17
PE20010071A1 (es) 2001-03-22
GB2351663A (en) 2001-01-10
FI20000976A0 (fi) 2000-04-26
ID25704A (id) 2000-11-02
NO322013B3 (no) 2017-11-06
CN1196487C (zh) 2005-04-13
CH1173181H1 (enExample) 2019-07-15
IL146098A (en) 2007-06-03
HU0001632D0 (en) 2000-06-28
GR1003575B (el) 2001-05-14
IE20000315A1 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
KR20010020779A (ko) 약학 제품
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US20030144296A1 (en) Daily treatment for erectile dysfunction using a PDE5 inhibitor
CZ20001536A3 (cs) Orální léčivo
HK1065485A (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20000426

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20010321

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20000426

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030630

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030924

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20030630

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I